Publications

Home » Pipeline » Publications
Publications

At Versartis, we’re committed to conducting research to guide and validate our treatment approaches, and to sharing what we’ve learned with the medical community through publications and at scientific forums. Read about our original research into the treatment of endocrine disorders with some of the world’s leading professionals in the field of endocrinology by clicking the links below.

ENDO 2017

Safety and Efficacy of Somavaratan (VRS-317), a Long-Acting Recombinant Human Growth Hormone (rhGH), in Children with Growth Hormone Deficiency (GHD): 3-Year Update of the VERTICAL & VISTA Trials (NCT01718041, NCT02068521). Presented at Endocrine Society’s 99th Annual Meeting & Expo. Orlando, Florida.

Abstract

Somavaratan, a Long-Acting Recombinant Human Growth Hormone (rhGH), for the Treatment of Adults with Growth Hormone Deficiency (AGHD): Results of VITAL, an Open-Label, Dose-Finding, International, Phase 2 Study (NCT02526420). Presented at Endocrine Society’s 99th Annual Meeting & Expo. Orlando, Florida.

Abstract

Achievement of a Suitable Basis of Comparison in Phase 2 and Phase 3 Pediatric Somavaratan Clinical Trials (VERTICAL, VISTA, and VELOCITY Studies) and for the Comparison of Somavaratan to Daily Recombinant Human Growth Hormone (rhGH). Presented at Endocrine Society’s 99th Annual Meeting & Expo. Orlando, Florida.

Abstract

Pharmacokinetic and Pharmacodynamic (PK/PD) Analysis of Somavaratan (VRS-317), a Long-Acting Recombinant Human Growth Hormone (rhGH), in Japanese and US Children with Growth Hormone Deficiency (GHD). Presented at Endocrine Society’s 99th Annual Meeting & Expo. Orlando, Florida.

Abstract

IGF Family Biomarkers in the Diagnosis of Pediatric Growth Hormone Deficiency (PGHD) in Somavaratan Clinical Trials. Presented at Endocrine Society’s 99th Annual Meeting & Expo. Orlando, Florida.

Abstract

Correlation Between Baseline IGF-I, Dose, and Response to Once-Monthly Somavaratan, a Long-Acting Recombinant Human Growth Hormone (rhGH), in the Open-Label, Dose-Finding, International, Phase 2 VITAL Study in Adults with Growth Hormone Deficiency (AGHD) (NCT02526420). Presented at Endocrine Society’s 99th Annual Meeting & Expo. Orlando, Florida.

Abstract

Moore W, et al. (2016). A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency.
The Journal of Clinical Endocrinology & Metabolism. 101:3, 1091-1097. March 2016.

Yuen KC, et al. (2013). A long-acting human growth hormone with delayed clearance (VRS-317): Results of a double-blind, placebo-controlled, single ascending dose study in growth hormone deficient adults.
The Journal of Clinical Endocrinology & Metabolism 98, 2595-2603.

Cleland JL, et al. (2012). A Novel Long-Acting Human Growth Hormone Fusion Protein (VRS-317): Enhanced In Vivo Potency and Half-Life.
Journal of Pharmaceutical Sciences, Vol. 101, No.8, August 2012.

Schellenberger V, et al. (2009) A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner.
Nature Biotechnology 27(12):1186-90.

Rosenfeld RG and Bakker B. (2008) Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr Pract. 2008;14(2)143-54.